SELLAS Life Sciences (SLS) Shares Outstanding (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Shares Outstanding (Entity) of $181.3 million for Q1 2026, up 99.49% year-over-year from $90.9 million in Q1 2025, and up 66.28% quarter-over-quarter from $109.1 million in Q4 2025.
SELLAS Life Sciences (SLS) Shares Outstanding (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Shares Outstanding (Entity) for 17 consecutive years, with $181.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 99.49% year-over-year to $181.3 million; the TTM figure through Mar 2026 stood at $181.3 million (up 99.49% YoY), while the FY2025 annual figure was $109.1 million, up 78.18% from the prior year.
- Shares Outstanding (Entity) rose to $181.3 million in Q1 2026 per SLS's latest filing, from $109.1 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $181.3 million in Q1 2026 and bottomed at $15.9 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $60.3 million across 5 years, with a median of $44.8 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) increased 5.44% — and 2024, when it surged 126.75%.
- SELLAS Life Sciences' Shares Outstanding (Entity) stood at $21.0 million in 2022, then surged by 52.97% to $32.1 million in 2023, then jumped by 90.47% to $61.2 million in 2024, then soared by 78.18% to $109.1 million in 2025, then soared by 66.28% to $181.3 million in 2026.
- Business Quant data shows SLS's Shares Outstanding (Entity) at $181.3 million in Q1 2026, $109.1 million in Q4 2025, and $125.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 172.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 189.18 Mn |
| Mar 31, 2026 | 172.48 Mn |
| Dec 31, 2025 | 109.05 Mn |
| Sep 30, 2025 | 108.40 Mn |
| Jun 30, 2025 | 98.56 Mn |
| Mar 31, 2025 | 87.76 Mn |
| Dec 31, 2024 | 61.20 Mn |
| Sep 30, 2024 | 68.25 Mn |
| Jun 30, 2024 | 57.63 Mn |
| Mar 31, 2024 | 44.81 Mn |
| Dec 31, 2023 | 27.78 Mn |
| Sep 30, 2023 | 28.36 Mn |
| Jun 30, 2023 | 28.35 Mn |
| Mar 31, 2023 | 23.55 Mn |
| Dec 31, 2022 | 19.40 Mn |
| Sep 30, 2022 | 20.56 Mn |
| Jun 30, 2022 | 20.29 Mn |
| Mar 31, 2022 | 15.90 Mn |
| Dec 31, 2021 | 15.48 Mn |
| Sep 30, 2021 | 15.87 Mn |